The drug development industry has seen significant changes in the last ten years. Amongst those changes, pharmaceutical and biotechnology sponsor companies are outsourcing more drug development activities to third party clinical research organisations. Alongside this, clinical trial technology is playing an increasingly critical role in drug development, as the range of technologies in the market increases and as those technologies become more effective and refined. As technology choices expand and relationships between sponsors and CROs deepen, Julian de Brés at Medidata Solutions and Chris Cramer at Quanticate provide an overview of why CROs need to alter their technology provider selection process to consider market drivers that didn’t exist just a few years ago.
http://jforcs.com/jcs/wp-content/uploads/edd/2012/09/Pages-from-JCS-Volume4Issue5-4.pdf